Bruce Krawiecki
Optometrist · Humble, TXNPI 1821093014
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Nordic Pharma, Inc. at 46.8% of the total. 2025 is the largest year on record at $36,017, 7.7 times the $4,674 reported in 2019. Among optometrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 474 payments — averaging $110.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nordic Pharma, Inc.$25K
- Tarsus Pharmaceuticals, Inc.$7K
- Alcon$5K
- AbbVie$5K
- Sun Pharmaceutical Industries Inc.$2K
- Biotissue Holdings Inc.$2K
- plus $7K from 22 others
What the payments were for
- Consulting fees$24,50047%
- Speaking & faculty fees$4,0958%
- Travel & lodging$3,3396%
- Food & beverage$20,38139%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nordic Pharma, Inc. | 1 | $24,500 |
| Tarsus Pharmaceuticals, Inc. | 42 | $6,689 |
| Alcon | 76 | $5,110 |
| AbbVie(2 entities) | 126 | $4,863 |
| Sun Pharmaceutical Industries Inc. | 46 | $1,851 |
| Biotissue Holdings Inc. | 15 | $1,808 |
| Oyster Point Pharma, Inc. | 23 | $804 |
| Novartis | 25 | $795 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $755 |
| Bausch & Lomb Americas Inc. | 20 | $720 |
| Glaukos Corporation | 8 | $567 |
| Carl Zeiss Meditec USA, Inc. | 8 | $513 |
| Aerie Pharmaceuticals, Inc. | 11 | $470 |
| Rayner Intraocular Lenses Limited | 3 | $345 |
| Eyevance Pharmaceuticals LLC | 5 | $315 |
| Dompe US, Inc. | 9 | $300 |
| NEW World Medical,inc. | 4 | $283 |
| Amgen(2 entities) | 2 | $264 |
| Sight Sciences, Inc. | 2 | $257 |
| Kala Pharmaceuticals, Inc. | 9 | $246 |
| Carl Zeiss Meditec, Inc. | 6 | $218 |
| Johnson & Johnson Vision Care, Inc. | 2 | $198 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $175 |
| Harrow Eye, LLC | 6 | $142 |
| Thea Pharma Inc. | 2 | $44 |
| Shire North American Group Inc | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Synergeyes, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lacrifill$24,500
- XDEMVY$5,678
- DAILIES$2,388
- AIR OPTIX$1,267
- DURYSTA$984
- CEQUA$851
- VUITY$638
- Prokera$581
- XIIDRA$465
- TYRVAYA$424
- LUMIGAN$380
- Rhopressa$380
- Rocklatan$380
- Hydrus Microstent$358
- RayOne EMV$300
- RayOne Spheric$300
- RayOne Aspheric$300
- TEPEZZA$264
- RESTASIS$249
- MIEBO$232
How this compares
$52,315 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 181 | $335,827 |
| RestasisCyclosporine | 89 | $112,980 |
| LumiganBimatoprost | 124 | $74,767 |
| MieboPerfluorohexyloctane/Pf | 52 | $42,674 |
| CequaCyclosporine | 41 | $40,471 |
| XiidraLifitegrast | 19 | $31,725 |
| Cyclosporine | 22 | $19,645 |
| RocklatanNetarsudil Mesylat/Latanoprost | 28 | $17,576 |
| Alphagan PBrimonidine Tartrate | 39 | $16,999 |
| CombiganBrimonidine Tartrate/Timolol | 42 | $14,158 |
| RhopressaNetarsudil Mesylate | 30 | $13,661 |
| VevyeCyclosporine | 15 | $10,844 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 53 | $10,722 |
| VyzultaLatanoprostene Bunod | 20 | $6,984 |
| Travoprost | 26 | $6,701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $6,689 | $335,827181 claims |
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $4,863 | $218,904294 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $720 | $81,38391 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,851 | $40,47141 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $470 | $31,23758 claims |
| Harrow Eye, LLCVevye | $142 | $10,84415 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $755 | $9,20039 claims |
| AlconSimbrinza | $5,110 | $5,42728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Humble
- Derek CunninghamAustin$940K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$547K
- Luis RojasMcKinney$309K
- Emile FadelAustin$225K
- Bridgitte LeeHouston$222K
- Phillip BrunsonHouston$214K
- Jill AutryBellaire$171K
- Stacie VirdenWaco$164K
- Richard PotvinBurleson$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.